Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

被引：15

作者：

Weinberg, Frank ^{[1
]}

Gadgeel, Shirish ^{[1
]}

机构：

[1] Univ Michigan, Dept Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA

来源：

LUNG CANCER-TARGETS AND THERAPY | 2019年 / 10卷

关键词：

NSCLC; immunotherapy; chemotherapy; clinical trials; PLATINUM-BASED CHEMOTHERAPY; OPEN-LABEL; DOUBLET CHEMOTHERAPY; 1ST-LINE TREATMENT; ADVANCED NSCLC; NIVOLUMAB; ATEZOLIZUMAB; DOCETAXEL; THERAPY; MULTICENTER;

D O I：

10.2147/LCTT.S176391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting programmed cell death 1 protein (PD-1) signaling pathway in the treatment of patients with NSCLC has had significant effect on patient survival. Atezolizumab, nivolumab and pembrolizumab have been shown to be superior to chemotherapy in patients with recurrent NSCLC. Recently, pembrolizumab has been combined with chemotherapy in the front-line setting and has demonstrated an improvement in overall survival in NSCLC patients as compared to chemotherapy alone. In this review we will focus on the clinical trials that led to approval of combination pembrolizumab and chemotherapy as first-line treatment for patients with advanced NSCLC as well as discuss other combinations of immunotherapy and chemotherapy that have also been evaluated.

引用

页码：47 / 56

页数：10

共 46 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[2]

BENNUN A, 2018, ANN ONCOL S8, V29, pR483, DOI DOI 10.1093/ANNONC/MDY290.011

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer [J].

Borghaei, Hossein ;

Langer, Corey J. ;

Gadgeel, Shirish ;

Papadimitrakopoulou, Vassiliki A. ;

Patnaik, Amita ;

Powell, Steven F. ;

Gentzler, Ryan D. ;

Martins, Renato G. ;

Stevenson, James P. ;

Jalal, Shadia I. ;

Panwalkar, Amit ;

Yang, James Chih-Hsin ;

Gubens, Matthew ;

Sequist, Lecia V. ;

Awad, Mark M. ;

Fiore, Joseph ;

Saraf, Sanatan ;

Keller, Steven M. ;

Gandhi, Leena .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) :124-129

[5] Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. [J].

Borghaei, Hossein ;

Hellmann, Matthew David ;

Paz-Ares, Luis G. ;

Ramalingam, Suresh S. ;

Reck, Martin ;

O'Byrne, Kenneth John ;

Bhagavatheeswaran, Prabhu ;

Nathan, Faith Ellen ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[6] Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].

Bracci, L. ;

Schiavoni, G. ;

Sistigu, A. ;

Belardelli, F. .

CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25

[7] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% [J].

Brahmer, J. ;

Rodriguez-Abreu, D. ;

Robinson, A. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Riccio, A. ;

Yang, J. ;

Pietanza, M. C. ;

Reck, M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1793-S1794

[8] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[9]

Cavanna Luigi, 2019, Oncotarget, V10, P209, DOI 10.18632/oncotarget.26541

[10] Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. [J].

Chaft, Jamie E. ;

Forde, Patrick M. ;

Smith, Kellie Nicole ;

Anagnostou, Valsamo ;

Cottrell, Tricia ;

Taube, Janis M. ;

Rekhtman, Natasha ;

Merghoub, Taha ;

Jones, David Randolph ;

Hellmann, Matthew David ;

Yang, Stephen C. ;

Broderick, Stephen ;

Rusch, Valerie W. ;

Velculescu, Victor E. ;

Topalian, Suzanne Louise ;

Pardo, Drew M. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →